Neurochemical findings in the MPTP model of Parkinson's disease

Journal of Neural Transmission

Volumn 108, Issue 11, 2001, Pages 1263-1282

  Schmidt, N ^a   Ferger, B ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

Animal models; MPTP; Neurodegeneration; Neurotoxicity; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM; CYTOKINE; GLUTAMIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITROGEN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BEHAVIOR; BIOTRANSFORMATION; BRAIN DEGENERATION; CALCIUM HOMEOSTASIS; CHRONICITY; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NECROSIS; NEUROCHEMISTRY; NEUROSCIENCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; HUMANS; MICE; MPTP POISONING; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 0035214256     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020100004     Document Type: Review

References (107)

1. Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia
2. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice
3. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases
4. Experimental models of Parkinson's disease
5. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
6. Oxidative damage and tyrosine nitration from peroxynitrite
7. Apparent hydroxyl radical production by peroxynitrite. Implications for endothelial injury from nitric oxide and superoxide
8. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus
9. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
10. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice
11. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice
12. Repeated administration of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurons
13. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
14. Critical review of rate constants for reactions of hydrated electrons, hydrated atoms and hydroxyl radicals
15. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP3)
16. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
17. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain
18. MPTP-induced ATP loss in mouse brain
19. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
20. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes
21. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autoxidation in the caudate nucleus: Effects of MPP+
22. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement
23. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
24. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57Bl/6 mice
25. Oxidative stress, glutamate, and neurodegenerative disorders
26. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model
27. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
28. Mitochondrial DNA and Parkinson's disease
29. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes
30. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity
31. Verteilung von noradrenalin und dopamin (3-hydroxytryptamin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems
32. Parkinsonism
33. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
34. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice
35. The protective effects of PBN against MPTP toxicity are independent of hydroxyl radical trapping
36. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate products
37. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
38. Increased MPTP neurotoxicity in vesicular monoamine transporter knockout mice
39. Animal models of Parkinson's disease: An empirical comparison with phenomenology of the disease in man
40. MPTP mechanisms of neurotoxicity and their implication for Parkinson's disease
41. 28k-containing cells
42. Environmental MPTP as a factor in the aetiology of Parkinson's disease?
43. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation
44. Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Identification of hydroxylated derivatives of salicylate in human bodyfluids
45. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: Neuroprotective strategies
46. Reactive oxygen species and the central nervous system
47. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons
48. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
49. Biochemical pathophysiology of Parkinson's disease
50. The reaction of NO with superoxide
51. Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease
52. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
53. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
54. MPTP-induced parkinsonism in the common marmoset: Behavioral and biochemical effects
55. Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice
56. Biomarkers of OH radical damage in vivo
57. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice
58. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
59. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse
60. A sensitive HPLC method for measuring highly reactive hydroxyl radicals in vitro and in vivo
61. Calcium ionfluxes mediate sustained release of endogenous striatal dopamine by toxic doses of MPP+ in vivo
62. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
63. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
64. Inducible nitric oxide synthase stimulates dopaminergic neurotransmission in the MPTP model of Parkinson's disease
65. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
66. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
67. Anatomy and pathology of the basal ganglia
68. Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: Effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine
69. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice
70. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion
71. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
72. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospi-nalfluid from parkinsonian patients
73. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum
74. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
75. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress
76. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
77. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease
78. Mechanisms of MPTP toxicity
79. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
80. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
81. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety
82. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide
83. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase
84. Older dopaminergic neurons do not recover from the effects of MPTP
85. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis
86. MPTP: A dopaminergic neurotoxin
87. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia
88. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat
89. Acute effects of intranigral application of MPP+ on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis
90. Progressive degeneration of nigrostriatal dopaminergic neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat
91. Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease
92. NF-kappaB is activated and promotes cell death in focal cerebral ischemia
93. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
94. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
95. Neurotransmitters and disorders of the basal ganglia
96. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
97. Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death
98. VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity
99. Cognitive changes in mice following moderate MPTP exposure
100. Parkinson's disease in twins: An etiologic study
101. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange
102. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
103. Nuclear factor-κB activation is not involved in a MPTP model of Parkinson's disease
104. Increased striatal dopamine turnover following acute administration of rotenone to mice
105. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
106. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
107. Distinct monoamine oxidase A and B populations in primate brain